



CO-FOUNDER NEEDED

Precision therapy for inflammation

Immunicorn Bio

THE PROBLEM

We are developing a safe treatment for severe inflammation with an initial focus on sepsis.

OUR SOLUTION

We target a beyond-rule-of-five therapeutic modality to inflamed tissues.

PATENT STATUS

NOI filed. Initial patentability search positive. We expect to file in Q3 2026.

FINANCIAL OVERVIEW

Biotech business model. Soft funding, followed by VC funding for preclinical and early clinical development.

Currently have soft funding from Independent Research Fund Denmark.

MILESTONES

In vitro proof-of-principle. Key partners identified.

We expect *in vivo* proof-of-concept in 6–12 months.

TARGET MARKET & CUSTOMERS

Partnering with Pharma.

Maturing and de-risking through investments.

CO-FOUNDER PROFILE

Preferred qualifications

- Fundraising and leading investor dialogues. Desire to take lead of commercial development in collaboration with the team at DTU.
- Experience with drug development from Biotech/Pharma.

Personal fit

- Bring a commercial mindset, drive soft and hard fundraising.
- Patience working with an early project.

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Get to know the the technology.

Develop a plan for platform development.

Scout initial soft funding options.

Identify KOLs and clinical stakeholders for the main applications.

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

Mads H. Clausen, professor, PhD.

Has co-founded three spin-outs.

Works with a co-founder on a vaccine project.

Henri Chédotal, postdoc, PhD.

Is new to entrepreneurship.

PHYSICAL ADDRESS

DTU Chemistry
Kemitorvet 207
2800 Kgs. Lyngby

Remote work is possible.



ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

www.open-entrepreneurship.com



SUPPORTED BY

Uddannelses- og
Forskningsministeriet